Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...
This week in cybersecurity: 338 new CVEs published including 11 critical severity. 9 vulnerabilities added to CISA KEV catalog. Plus major developments in AI security, supply chain attacks, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results